Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

TaiGen, HEC form hepatitis venture

by Jean-François Tremblay
November 7, 2016 | A version of this story appeared in Volume 94, Issue 44

TaiGen Biotechnology and HEC Pharmaceutical are forming a joint venture to develop hepatitis C virus treatments for China. HEC will get a 51% stake for funding construction of a plant and contributing a drug candidate, yimitasvir, that recently started clinical trials in China. TaiGen will get a 49% stake for contributing furaprevir, which is undergoing Phase II trials in China and Taiwan. The two candidates—both oral drugs for interferon-free HCV regimens—are likely to be approved in China because they are similar to existing drugs, says Tommy Lin, HEC’s director of business development and licensing.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.